Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/129699
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Inflammation in coronary atherosclerosis and its therapeutic implications |
Author: | Montarello, N.J. Nguyen, M.T. Wong, D.T.L. Nicholls, S.J. Psaltis, P.J. |
Citation: | Cardiovascular Drugs and Therapy, 2022; 36(2):347-362 |
Publisher: | Springer Nature |
Issue Date: | 2022 |
ISSN: | 0920-3206 1573-7241 |
Statement of Responsibility: | Nicholas J. Montarello, Mau T. Nguyen, Dennis T.L. Wong, Stephen J. Nicholls, Peter J. Psaltis |
Abstract: | Atherosclerotic coronary artery disease has a complex pathogenesis which extends beyond cholesterol intimal infiltration. It involves chronic inflammation of the coronary artery wall driven by systemic and local activation of both the adaptive and innate immune systems, which can ultimately result in the rupture or erosion of atherosclerotic plaque, leading to thrombosis and myocardial infarction (MI). Despite current best practice care, including the widespread use of cholesterol-lowering statins, atherothrombotic cardiovascular events recur at alarming rates post-MI. To a large extent, this reflects residual inflammation that is not adequately controlled by contemporary treatment. Consequently, there has been increasing interest in the pharmacological targeting of inflammation to improve outcomes in atherosclerotic cardiovascular disease. This has comprised both novel pathway-specific agents, most notably the anti-interleukin-1 beta monoclonal antibody, canakinumab, and the repurposing of established, broad-acting drugs, such as colchicine, that are already approved for the management of other inflammatory conditions. Here we discuss the importance of inflammation in mediating atherosclerosis and its complications and provide a timely update on "new" and "old" anti-inflammatory therapies currently being investigated to target it. |
Keywords: | Inflammation Atherosclerosis; canakinumab; clonal hematopoiesis; colchicine; epicardial adipose tissue; inflammation |
Description: | Published online: 10 November 2020 |
Rights: | © Springer Science+Business Media, LLC, part of Springer Nature 2020 |
DOI: | 10.1007/s10557-020-07106-6 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/GNT1161506 |
Published version: | http://dx.doi.org/10.1007/s10557-020-07106-6 |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.